Upadacitinib
also Rinvoq
- Approved (Rinvoq) · oral · AbbVie · EMA approved · FDA pending · Severe alopecia areata only
JAK inhibitor sold as Rinvoq; approved in the EU for severe alopecia areata, under FDA review for it
Upadacitinib, sold under the brand name Rinvoq, is a medication used for the treatment of rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, Crohn's disease, ankylosing spondylitis, and axial spondyloarthritis. Upadacitinib is a Janus kinase (JAK) inhibitor that works by blocking the action of enzymes called Janus kinases. These enzymes are involved in setting up processes that lead to inflammation, and blocking their effect brings inflammation in the joints under control.
Read “Upadacitinib” on Wikipedia · text from Wikipedia, CC BY-SA 4.0
Information, not medical advice. Talk to a licensed doctor or pharmacist before starting or changing a treatment.
Research 10
- Effective treatment of alopecia universalis with oral upadacitinib
- Upadacitinib for the Management of Alopecia Totalis and Subtotalis in Pediatric Patients: A Case Series
- Upadacitinib for management of recalcitrant alopecia areata: A retrospective case series
- Upadacitinib for Alopecia Areata in Different Backgrounds: A Case Series
- Upadacitinib for Alopecia: Current Evidence and Clinical Insights
- Long-term efficacy and safety of upadacitinib in the treatment of alopecia areata: A retrospective study
- Concomitant management of alopecia universalis and ulcerative colitis with upadacitinib
- Alopecia Universalis in an Adolescent Successfully Treated with Upadacitinib—A Case Report and Review of the Literature on the Use of JAK Inhibitors in Pediatric Alopecia Areata
- Alopecia Areata – Effects of Treatment with Upadacitinib – Two Case Reports
- Management of comorbid Crohn’s disease and alopecia universalis with upadacitinib and oral minoxidil
- Comparative Efficacy of Ritlecitinib, Baricitinib, and Upadacitinib in Adolescents With Severe Alopecia Areata: A Bayesian Network Meta‑Analysis
- Janus kinase inhibitors in the management of lichen planus: a systematic review
- Monitoring the Response to JAK Inhibitor Treatment in Alopecia Areata Using Reflectance Confocal Microscopy and Videotrichoscopy: A 60-Week Observational Study
- Long-term upadacitinib treatment in a patient with atopic dermatitis, bullous pemphigoid, and alopecia areata: a case report and review of the literature
- Pediatric alopecia areata and JAK inhibitors: Bridging the gap between evidence and practice
- Successful treatment of coexisting alopecia areata and hidradenitis suppurativa with upadacitinib
- Upadacitinib for Severe Alopecia Areata in Adults and Adolescents
- Lupus Miliaris Disseminatus Faciei and Follicular Mucinosis: A New Pattern of Janus Kinase Inhibitor Acneiform Eruption
- JAK Inhibitor Safety in Atopic Dermatitis and Alopecia Areata: A 4.5-Year Real-World Retrospective Cohort Study
- Long-term efficacy and safety of upadacitinib in the treatment of alopecia areata: A retrospective study
Posts 7
- Are we still getting the PP405 phase 2a results by the end of March?
- Lab results from actifolic RU58841
- Breezula 6 Month Topline Phase III Results Released
- Anyone tried switching from RU to Pyrilutamide (KX-826)
- Anyone long term experience with FYNZUR 2,275 mg/ml spray?
- Revivogen MD product actually working
- ru58841: Anyone have experience with this?